Led · Series A · Jul 2026

SoundHealth develops personalized, AI-enabled, non-invasive medical and wellness devices targeting breathing and sleep disorders. Its flagship FDA-cleared Sonu band has delivered more than 500,000 acoustic resonance treatment sessions for users ages 12 and up and is described as a leading steroid alternative for congestion due to allergic and non-allergic rhinitis. The company has built a craniofacial anatomical dataset used to personalize treatments and to underpin its Spatial Sleep product, which the company says is the world’s first clinically proven personalized sleep wellness device and has been shown to help users fall asleep faster and sleep longer. SoundHealth is recommended by more than 1,000 medical and dental professionals nationwide. Following the Series A, the company has $12.25 million in total funding to date to support further growth and commercialization.

Participated · Series B · Apr 2026

Nervonik is developing a next-generation peripheral nerve stimulation platform that combines electrical stimulation with advanced sensing to enable more precise, personalized neuromodulation therapies. Its implantable leads have demonstrated the ability to record evoked compound action potentials (ECAPs) and other physiological biomarkers. The company is advancing clinical programs and preparing for commercialization of its PNS system. Recent financing will fund further development of its proprietary sensing capabilities and support commercialization activities. Nervonik is headquartered in Los Angeles, California.

Participated · Series A · Oct 2025

Petal Surgical is developing an incisionless surgery platform that uses Millisecond Pulse Histotripsy — a form of acoustic liquefaction — integrated with robotics, imaging and AI-driven controls to precisely treat tissue. The platform creates vapor-filled cavities one at a time to enable connected treatment regions and break down tougher tissues without cutting. The company says its approach aims to eliminate cuts, pain, trauma and other typical surgical risks and to leverage the body's natural healing. Petal plans to use recent financing to accelerate R&D, expand clinical readiness activities and advance toward first-in-human studies. The company was founded by image-guided surgery engineer Prash Chopra alongside neurosurgeon Dr. Bowen Jiang, spine-surgery pioneer Dr. Nicholas Theodore, and Rony Abovitz, a founder of Mako Surgical. Petal has drawn board and investor support from figures such as Dr. Fred Moll and Lip-Bu Tan.

Participated · Series D · Aug 2025

SetPoint Medical is a commercial-stage medical technology company headquartered in Valencia, Calif., focused on therapies for chronic autoimmune diseases. Its FDA‑approved SetPoint System is the first neuroimmune modulation therapy for adults with moderate-to-severe rheumatoid arthritis, providing a device-based alternative for patients who do not respond to or cannot tolerate biologic or targeted drug therapies. The company’s proprietary integrated neurostimulation platform is designed to activate innate anti-inflammatory pathways in the vagus nerve to reduce inflammation and restore immunologic setpoint. Proceeds from the recent financing will support commercialization of the SetPoint System in select U.S. markets this year and broader national expansion in 2026, and will also fund advancement of the company’s pipeline in other autoimmune conditions. SetPoint plans to evaluate its platform for additional indications including multiple sclerosis and Crohn’s disease. In conjunction with the fundraise the company expanded its leadership team and board to support commercialization and market access efforts. SetPoint Medical is a privately held clinical-stage healthcare company focused on treating chronic autoimmune diseases. The company is developing a novel platform that stimulates the vagus nerve to activate the inflammatory reflex and produce a systemic immune-restorative effect. The SetPoint system is a miniaturized stimulation device placed on the vagus nerve through a small incision on the left side of the neck in an outpatient procedure and delivers stimulation on a preset schedule. The platform is being developed as an alternative for patients with rheumatoid arthritis who have an incomplete response to or are intolerant of biologic drugs, and is also intended for inflammatory bowel disease and other chronic autoimmune conditions. SetPoint is advancing the RESET-RA study and preparing U.S. FDA regulatory submissions and early commercialization for the RA indication. Financially, the company recently announced an $80 million equity financing and expanded a senior secured term loan facility of up to $65 million with Runway Growth Capital to support development and early commercial activities. SetPoint Medical develops a bioelectronic medicine platform designed to stimulate the vagus nerve and activate the body’s inflammatory reflex to produce a systemic immune‑restorative effect for chronic autoimmune diseases. The company is pursuing electrical‑pulse therapies as a potentially safer, lower‑cost alternative to drugs and biologics for conditions including rheumatoid arthritis and inflammatory bowel disease. SetPoint is clinical‑stage and is advancing its technology through the RESET‑RA study, which will evaluate safety and efficacy in patients with moderate‑to‑severe RA. The $35 million financing announced will support the ongoing RESET‑RA trial and other development activities. SetPoint is privately held, was founded in 2007, and is based in Valencia, California. The articles do not disclose revenue or user metrics. SetPoint Medical is a privately held, clinical‑stage bioelectronic medicine company developing a platform that stimulates the vagus nerve to activate the inflammatory reflex and reduce systemic inflammation. The company is initially focused on a less immunosuppressive therapeutic option for patients with rheumatoid arthritis (RA) and is also developing applications for inflammatory bowel disease and other chronic autoimmune conditions. SetPoint’s investigational device is intended to offer an alternative to biologic and targeted drug therapies with potentially lower risk and cost. The company has received Breakthrough Device designation from the U.S. FDA for use in RA patients who are incomplete responders to, or intolerant of, multiple biologic drugs. Proceeds from the financing will support the RESET‑RA multicenter, double‑blind, randomized, sham‑controlled pivotal trial that will enroll up to 250 patients at 40 U.S. sites to evaluate safety and effectiveness. SetPoint converts neurostimulation of the vagus nerve into a systemic immune‑restorative effect and is positioning its platform toward regulatory‑pathway clinical validation. SetPoint Medical is developing a proprietary bioelectronic medicine platform that uses a small implanted device to activate the body’s Inflammatory Reflex and produce a systemic anti-inflammatory effect. The company’s core product is an implanted stimulator that targets the vagus nerve as an alternative to drug therapies for chronic inflammatory diseases. SetPoint has published positive results from a first‑in‑human proof‑of‑concept trial in rheumatoid arthritis in PNAS and presented positive data at the American College of Rheumatology meeting. The company positions its approach as potentially lower risk and lower cost compared with current biologic treatments. SetPoint plans to use the new financing to advance clinical development and enable its next clinical trial in rheumatoid arthritis. It is a privately held company focused on commercializing bioelectronic medicines for debilitating inflammatory diseases.

Participated · Series A · Dec 2024

Fluid Biomed is a clinical-stage medical device company based in Calgary, Alberta, developing ReSolv™, the world’s first bioabsorbable polymer-based neurovascular stent for brain aneurysms. The ReSolv™ stent has been validated by years of scientific research and demonstrated functional benefits in a first-in-human clinical study. The technology was developed by co-founders John Wong, M.D. (CEO), and Alim Mitha, M.D. (President and CTO), both academic neurosurgeons at the University of Calgary. The company plans to use recent financing to further validate the ReSolv™ stent and its proprietary delivery system in expanded patient studies and to enable larger clinical trials. Fluid Biomed also intends to broaden its product pipeline with the additional strategic and financial capital. Fluid Biotech is commercializing a hybrid polymer-metal flow-diverting brain stent constructed of bioabsorbable polymer and metal to provide a scaffold that enables better healing and vessel visualization. Led by Dr. John Wong (CEO) and Dr. Alim Mitha (President and CTO), the company aims to cure intracranial aneurysms with this novel device. Fluid closed a $4.7M seed funding round to advance development. The company intends to use the funds to engage contract manufacturers to initiate production, complete regulatory milestones, and plan for first-in-human implantation. In conjunction with the raise, Fluid added two board members with capital and industry experience to support commercialization and regulatory progress. The company is based in Calgary, Alberta, Canada.